Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Malaria Rapid Diagnostic Test Evaluated At Point-Of-Care

By LabMedica International staff writers
Posted on 22 Apr 2015
For over a decade, the development of malaria rapid diagnostic tests (RDTs) has enabled reliable biological diagnostic testing in all situations where previously only clinical diagnosis was available. More...
These RDTs are generally considered as point-of-care tests.

Most of the studies assessing the performance of malaria RDTs are conducted by trained scientific teams that are not representative of the classical end-users, who are typically unskilled in traditional laboratory techniques for diagnosing malaria. Consequently, only the basic performance of malaria RDTs is evaluated and information regarding their overall performance when they are used by the traditional end-users is lacking.

Scientists at the Institut Pasteur du Cambodge (Phnom Penh, Cambodia) tested three types of sample (negative, low positive, high positive) in replicates of four, corresponding to a panel of 20 aliquots, as followed: one negative sample, one low positive sample at 200 parasites of Plasmodium falciparum/μL, one low positive sample at 200 parasites of P. vivax/μL, one high positive sample at 2,000 parasites of P. falciparum/μL and one high positive sample at 2,000 parasites of P. vivax/μL. Twenty end-users with four different profiles in seven communes in Kampot Province (Cambodia) were selected.

The ready-to-use cassette device the VIKIA Malaria Ag Pf/Pan (IMACCESS/bioMérieux; Lyon, France) was the RDT used. This test is based on immunochromatographic technology for detecting P. falciparum and other species of Plasmodium (P. vivax, P. malariae, and P. ovale). The team performed a quality control assessment of the set of the 20 aliquots at three different times (at the start, middle and end of the study), to confirm the good quality of the aliquots distributed to the users and to verify that no degradation occurred during transport or storage that could affect the expected results.

All results obtained by the end-users were consistent with the expected results, except for the low positive (200 parasites/μL) P. vivax aliquot (35% of concordant results). No significant difference was observed between the different end-users. End-user interviews evaluating ease-of-use and ease-of-reading of the VIKIA Malaria Ag Pf/Pan kit recorded 159 positive answers and only one negative answer. Out of 20 end-users, only one considered the test was not easy to perform with the support of the quick guide.

The authors concluded that the performance of the VIKIA Malaria AgPf/Pan rapid test performed by traditional end-users in field conditions is similar to those obtained by a trained scientific team, and that VIKIA Malaria AgPf/Pan can be considered as a point-of-care test. In addition, the protocol designed for this study, using well-characterized and calibrated blood samples could be used systematically in parallel to conventional evaluation studies to determine the performance of malaria RDTs in field conditions. The study was published on March 14, 2015, in the Malaria Journal.

Related Links:

Institut Pasteur du Cambodge 
IMACCESS/bioMérieux 



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.